GlassScriptPhysician profile
Mohammed Alfaiyumi
NPI 1063612687
$821.34
in general payments reported to CMS, 2019-2025
11 companies · $50.67 in 2025
The $50.67 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $195 · 2020: $93.84 · 2021: $12.68 · 2022: $33.31 · 2023: $219 · 2024: $217 · 2025: $50.67.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $486.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $486.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $157.27 | 2023-2024 | |
| Pulmonx Corporation | $144.74 | 2023 | Pulmonx Chartis Tablet Console, Zephyr Delivery Catheter, Zephyr Endobronchial Valve |
| Glaxosmithkline, LLC. | $137.12 | 2019-2024 | Nucala |
| Genentech USA, INC. | $85.95 | 2019-2020 | |
| Pfizer INC. | $67.40 | 2020-2025 | |
| Astrazeneca Pharmaceuticals LP | $61.02 | 2019-2023 | Fasenra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $60.59 | 2019-2020 | |
| Philips North America LLC | $33.31 | 2022 | |
| Baxter Healthcare | $31.91 | 2025 | Hillrom - Vest System Model 105 Home Care |
| United Therapeutics Corporation | $21.34 | 2023 | Tyvaso |
| Resmed Corp | $20.69 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohammed Alfaiyumi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.